Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...
Keep an eye on the future but hone your coding craft in the now. Start here, with nine timeless JavaScript coding concepts, a ...
TipRanks on MSN
Recursion Pharmaceuticals rises 17.9%
Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17. Published first on TheFly – the ultimate source for real-time, market-moving ...
We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback